Tag Archives: Dewey Steadman

Endo International plc (ENL) Got Some Good News

According to The Fly, in a new note to investors today, an analyst has provided a rating update for the Healthcare company, Endo International plc (ENL – Research Report). Canaccord Genuity’s analyst Dewey Steadman upgraded ENL to Buy. According to

Endo International (ENDP) Got Some Good News

Canaccord Genuity analyst Dewey Steadman upgraded Endo International (ENDP – Research Report) to Buy today and set a price target of $20. The company’s shares closed yesterday at $13.19. According to TipRanks.com, Steadman is a 1-star analyst with an average

Canaccord Genuity Believes Correvio Pharma Corp. (TSX: CORV) Won’t Stop Here

Correvio Pharma Corp. (TSX: CORV), the Healthcare company, has received a rating update from a Wall Street analyst today. The company received a Buy rating from Canaccord Genuity’s analyst Dewey Steadman, with a C$8 price target. According to TipRanks.com, Steadman

Amneal Pharmaceuticals Inc (AMRX) Receives a Hold from Canaccord Genuity

Canaccord Genuity analyst Dewey Steadman maintained a Hold rating on Amneal Pharmaceuticals Inc (NYSE: AMRX) yesterday and set a price target of $21. The company’s shares opened today at $22.97, close to its 52-week high of $24.48. According to TipRanks.com,

Canaccord Genuity Keeps a Hold Rating on Amneal Pharmaceuticals Inc (AMRX)

In a report released today, Dewey Steadman from Canaccord Genuity maintained a Hold rating on Amneal Pharmaceuticals Inc (NYSE: AMRX), with a price target of $21. The company’s shares opened today at $23.85, close to its 52-week high of $24.48.

Amneal Pharmaceuticals Inc (AMRX) Gets a Hold Rating from Canaccord Genuity

In a report released today, Dewey Steadman from Canaccord Genuity maintained a Hold rating on Amneal Pharmaceuticals Inc (NYSE: AMRX), with a price target of $21. The company’s shares opened today at $22.05. Steadman said: “We expect the deal to